Sugi Predict

Sugi Predict / Targets / PIM3

PIM3

Serine/threonine-protein kinase pim-3 · Q86V86 · PIM3 on Sugi Atlas →

107,503 patent compounds predicted against PIM3, 61,435 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL319071 SCHEMBL319071 0.64 20/20
SCHEMBL319029 SCHEMBL319029 0.63 20/20
SCHEMBL319072 SCHEMBL319072 0.60 20/20
SCHEMBL319325 SCHEMBL319325 0.57 20/20
SCHEMBL319581 SCHEMBL319581 0.56 20/20
SCHEMBL319019 SCHEMBL319019 0.56 20/20
SCHEMBL319494 SCHEMBL319494 0.55 20/20
SCHEMBL318980 SCHEMBL318980 0.54 20/20
SCHEMBL319635 SCHEMBL319635 0.54 20/20
SCHEMBL319834 SCHEMBL319834 0.54 20/20
SCHEMBL319256 SCHEMBL319256 0.53 20/20
SCHEMBL319399 SCHEMBL319399 0.53 20/20
SCHEMBL319793 SCHEMBL319793 0.53 20/20
SCHEMBL320006 SCHEMBL320006 0.53 20/20
SCHEMBL319655 SCHEMBL319655 0.51 20/20
SCHEMBL318751 SCHEMBL318751 0.50 20/20
SCHEMBL319394 SCHEMBL319394 0.59 19/20
SCHEMBL319025 SCHEMBL319025 0.58 19/20
SCHEMBL319198 SCHEMBL319198 0.58 19/20
SCHEMBL319404 SCHEMBL319404 0.55 19/20

Clinical trials — most relevant to PIM3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma PHASE2/PHASE3COMPLETED
Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders PHASE2RECRUITING
Study in Adult Ph-positive ALL PHASE2UNKNOWN
A Phase II Study of Dasatinib in the Treatment of Relapsed or Plateau Phase Multiple Myeloma PHASE2COMPLETED
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer PHASE2COMPLETED
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma PHASE1/PHASE2SUSPENDED
The Clinical Study of Apatinib Plus S1 for Patients With Advanced Non-squamous Head and Neck Cancer PHASE2UNKNOWN
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy PHASE2COMPLETED
Apatinib With Ifosfamide Plus Etoposide for Relapsed or Refractory Osteosarcoma (OAIE) PHASE2COMPLETED
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H... PHASE2COMPLETED
Apatinib as Second-line Treatment of Advanced Pancreatic Cancer PHASE2UNKNOWN
A Study to Investigate The Effect of Pimicotinib on The Pharmacokinetics of Metformin, Fexofenadine and Rosuvastatin In Healthy Subjects PHASE1COMPLETED
Sirolimus and Gold Sodium Thiomalate in Treating Patients With Advanced Squamous Non-Small Cell Lung Cancer PHASE1WITHDRAWN
Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients PHASE1COMPLETED
Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers PHASE1COMPLETED
A Study of Mobocertinib in Japanese Adults With Non-Small Cell Lung Cancer PHASE1ACTIVE_NOT_RECRUITING
A Study to Evaluate the Relative Bioavailability of Pimicotinib Capsules Containing Free Base in Different Proportions in Healthy Subjects PHASE1COMPLETED
Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the Treatment of Relapsed / Refractory Acute Myeloid Leukemia PHASE1RECRUITING
Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG) PHASE1COMPLETED
Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia PHASE1RECRUITING
Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer PHASE1ACTIVE_NOT_RECRUITING
Auranofin and Sirolimus in Treating Patients With Advanced Solid Tumors or Recurrent Non-Small Cell Lung Cancer PHASE1WITHDRAWN
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer PHASE1COMPLETED
Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma EARLY_PHASE1RECRUITING
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma nanCOMPLETED
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients nanCOMPLETED
Ischemic Preconditioning - Perspectives of Use Vivio/in Vitro Studies nanENROLLING_BY_INVITATION
Evaluation of Hypoxia in Primary Melanoma nanRECRUITING
Immune Interactions in Severe Asthma nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PIM3 binder may also engage these)

ProteinNameSimilarity
P58750 — 1.000 P58750 →
O70444 — 1.000 O70444 →
Q9PU85 — 0.989 Q9PU85 →
P26794 — 0.986 P26794 →
Q91822 — 0.983 Q91822 →
P06803 — 0.983 P06803 →
Q95LJ0 — 0.979 Q95LJ0 →
O88764 — 0.977 O88764 →
Q5RCY1 — 0.977 Q5RCY1 →
Q63285 — 0.976 Q63285 →
Q9R011 — 0.976 Q9R011 →
P55203 — 0.976 P55203 →
ULK3 Serine/threonine-protein kinase ULK3 0.975 landscape →
Q62070 — 0.975 Q62070 →
Q6ERS4 — 0.975 Q6ERS4 →
P17105 — 0.975 P17105 →
Q9N0P9 — 0.974 Q9N0P9 →
P52785 — 0.974 P52785 →
EPHB4 Ephrin type-B receptor 4 0.974 landscape →
P63319 — 0.974 P63319 →
P63318 — 0.974 P63318 →
Q4R4U2 — 0.973 Q4R4U2 →
PRKCG Protein kinase C gamma type 0.973 landscape →
D3ZHP7 — 0.973 D3ZHP7 →
PIM1 Serine/threonine-protein kinase pim-1 0.972 landscape →
Q7XIW5 — 0.972 Q7XIW5 →
O09127 — 0.972 O09127 →
P70218 — 0.971 P70218 →
RPS6KA4 Ribosomal protein S6 kinase alpha-4 0.971 landscape →
Q9Z2B9 — 0.971 Q9Z2B9 →